HLB Life Science Obtains Tissue Bank Approval...Expands Human Tissue Graft Business

HLB Life Science announced on March 24 that it will accelerate the expansion of its human tissue graft business following its acquisition of tissue bank authorization.

Acellular allogeneic dermal injection 'FreedomInject Refill.' HLB Life Science

This authorization follows the company’s domestic exclusive distribution agreement signed last month with Orthotech, a medical device specialist, for human tissue grafts.

The product that HLB Life Science will distribute, 'FreedomInject Refill,' is an acellular allogeneic dermal injection derived from human tissue. Utilizing skin as its primary material, this human tissue-based product is used for treating damaged ligaments, tendons, muscles, and for surgical supplementation. Because it can be stored at room temperature, it is expected to offer enhanced convenience for use in medical settings.

This product is a medical biomaterial in which cells and fat components are removed from skin-derived tissue, while extracellular matrix components such as collagen—essential for tissue regeneration—are preserved as much as possible. It is expected to be widely applicable for the reconstruction, regeneration, and recovery of damaged soft tissue and joints.

HLB Life Science anticipates that, with this tissue bank authorization, it will be able to broaden its business into a wider range of human tissue-based products. The supply targets include orthopedic, neurosurgery, obstetrics and gynecology, and urology clinics nationwide, with plans to gradually expand its distribution channels in the future.

Yoonki Baek, the CEO-designate of HLB Life Science, stated, "This tissue bank authorization is significant in that it provides a key foundation for accelerating our human tissue graft business. We will continue to create new growth engines in the field of regenerative medicine, as well as expand domestic supply."

This content was produced with the assistance of AI translation services.